Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Research & Development (2024 - 2025)

Maze Therapeutics has reported Research & Development over the past 2 years, most recently at $27.6 million for Q4 2025.

  • Quarterly Research & Development rose 24.1% to $27.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $108.4 million through Dec 2025, up 29.88% year-over-year, with the annual reading at $108.4 million for FY2025, 29.88% up from the prior year.
  • Research & Development was $27.6 million for Q4 2025 at Maze Therapeutics, up from $25.2 million in the prior quarter.
  • Over five years, Research & Development peaked at $28.1 million in Q2 2025 and troughed at $19.5 million in Q2 2024.